Compare $KTTA vs $TCRX | Chartloom

Compare

$KTTA vs $TCRX

Pasithea Therapeutics Corp · TScan Therapeutics Inc

KTTA

Pasithea Therapeutics Corp

TCRX

TScan Therapeutics Inc

Compare $KTTA vs $TCRX

Comparing Pasithea Therapeutics Corp and TScan Therapeutics Inc

KTTAPasithea Therapeutics Corp

TCRXTScan Therapeutics Inc

KTTAPasithea Therapeutics Corp

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

740.5%

YTD performance

-60.7%

52W performance

-43.0%

FCF yield

-113.8%

TCRXTScan Therapeutics Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

8.85x

Rev growth (TTM)

2.2%

YTD performance

-76.7%

52W performance

-88.0%

FCF yield

-761.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KTTA

TCRX

Detailed metrics comparison

KTTA

Pasithea Therapeutics Corp

TCRX

TScan Therapeutics Inc

Market Cap

KTTA$16M

TCRX$16M

Enterprise Value

KTTA$-30M

TCRX$-52M

Price

KTTA$0.47

TCRX$0.24

P/E Ratio

KTTAN/A

TCRXN/A

P/S Ratio

KTTA26.84x

TCRX2.19x

EV/Sales

KTTA0.00x

TCRX-7.29x

EV/EBITDA

KTTA0.00x

TCRX0.00x

P/B Ratio

KTTA0.32x

TCRX0.31x

P/FCF Ratio

KTTAN/A

TCRXN/A

EV/FCF

KTTA1.69x

TCRX0.44x

PEG Ratio

KTTAN/A

TCRXN/A

Forward P/E (NTM)

KTTAN/A

TCRXN/A

Forward P/S (NTM)

KTTAN/A

TCRX8.85x

Revenue (TTM)

KTTA$0

TCRX$7M

Revenue Growth (YoY)

KTTA740.5%

TCRX2.2%

Forward Rev Growth

KTTA0.0%

TCRX42.6%

Gross Margin (TTM)

KTTA100.5%

TCRX0.0%

Operating Margin (TTM)

KTTA0.0%

TCRX0.0%

EBITDA Margin (TTM)

KTTA0.0%

TCRX-1626.5%

Net Margin (TTM)

KTTA0.0%

TCRX-1655.4%

FCF Margin (TTM)

KTTAN/A

TCRX-1665.6%

Net Income (TTM)

KTTA$-21M

TCRX$-118M

FCF (TTM)

KTTA$-18M

TCRX$-118M

EPS (TTM)

KTTA-$0.66

TCRX-$0.91

ROE (TTM)

KTTA-4949.0%

TCRX-10872.0%

ROA (TTM)

KTTA-4681.0%

TCRX-5447.0%

ROIC (TTM)

KTTA-4949.0%

TCRX-8356.0%

Cash

KTTA$46M

TCRX$100M

Debt

KTTA$0

TCRX$33M

Net Cash/Debt

KTTA$46M

TCRX$67M

Current Ratio (TTM)

KTTA26.25x

TCRX3.37x

Quick Ratio (TTM)

KTTA24.91x

TCRX3.23x

Debt/Equity (TTM)

KTTA0.00x

TCRX0.47x

Debt/Assets (TTM)

KTTA0.0%

TCRX0.0%

Interest Coverage (TTM)

KTTAN/A

TCRXN/A

Net Debt/EBITDA (TTM)

KTTA0.00x

TCRX0.00x

Beta

KTTA0.39

TCRX1.19

52W Performance

KTTA-43.0%

TCRX-88.0%

YTD Performance

KTTA-60.7%

TCRX-76.7%

% from 52W High

KTTA-77.3%

TCRX-90.7%

% from 52W Low

KTTA66.4%

TCRX6.1%

Asset Turnover (TTM)

KTTA0.01x

TCRX0.03x

FCF Yield (TTM)

KTTA-113.8%

TCRX-761.5%

Earnings Yield (TTM)

KTTA-136.3%

TCRX-756.8%

Dividend Yield (TTM)

KTTAN/A

TCRXN/A

Rule of 40

KTTA740.5

TCRX-1,663.4

EV/GP/RG

KTTAN/A

TCRXN/A

Ticker research

View KTTA research View TCRX research

Metric	KTTA Pasithea Therapeutics Corp	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$16M	$16M
Enterprise Value	$-30M	$-52M
Price	$0.47	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	26.84x	2.19x
EV/Sales	0.00x	-7.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.32x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	1.69x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.85x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	740.5%	2.2%
Forward Rev Growth	0.0%	42.6%
Profitability
Gross Margin (TTM)	100.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1626.5%
Net Margin (TTM)	0.0%	-1655.4%
FCF Margin (TTM)	N/A	-1665.6%
Net Income (TTM)	$-21M	$-118M
FCF (TTM)	$-18M	$-118M
EPS (TTM)	-$0.66	-$0.91
ROE (TTM)	-4949.0%	-10872.0%
ROA (TTM)	-4681.0%	-5447.0%
ROIC (TTM)	-4949.0%	-8356.0%
Financial Health
Cash	$46M	$100M
Debt	$0	$33M
Net Cash/Debt	$46M	$67M
Current Ratio (TTM)	26.25x	3.37x
Quick Ratio (TTM)	24.91x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	1.19
52W Performance	-43.0%	-88.0%
YTD Performance	-60.7%	-76.7%
% from 52W High	-77.3%	-90.7%
% from 52W Low	66.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.03x
FCF Yield (TTM)	-113.8%	-761.5%
Earnings Yield (TTM)	-136.3%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	740.5	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View KTTA research	View TCRX research

Valuation

P/S Ratio

TCRX

2.19x

KTTA

26.84x

EV/FCF

TCRX

0.44x

KTTA

1.69x

Growth & revenue

Revenue Growth TTM

KTTA

740.5%

TCRX

2.2%

Forward Revenue Growth

TCRX

42.6%

KTTA

0.0%

Profitability & performance

Gross Margin

KTTA

100.5%

TCRX

0.0%

ROE

KTTA

-4949.0%

TCRX

-10872.0%

FCF Yield %

KTTA

-113.8%

TCRX

-761.5%

52-Week Performance

KTTA

-43.0%

TCRX

-88.0%

Detailed metrics comparison

KTTA

Pasithea Therapeutics Corp

TCRX

TScan Therapeutics Inc

Market Cap

KTTA$16M

TCRX$16M

Enterprise Value

KTTA$-30M

TCRX$-52M

Price

KTTA$0.47

TCRX$0.24

P/E Ratio

KTTAN/A

TCRXN/A

P/S Ratio

KTTA26.84x

TCRX2.19x

EV/Sales

KTTA0.00x

TCRX-7.29x

EV/EBITDA

KTTA0.00x

TCRX0.00x

P/B Ratio

KTTA0.32x

TCRX0.31x

P/FCF Ratio

KTTAN/A

TCRXN/A

EV/FCF

KTTA1.69x

TCRX0.44x

PEG Ratio

KTTAN/A

TCRXN/A

Forward P/E (NTM)

KTTAN/A

TCRXN/A

Forward P/S (NTM)

KTTAN/A

TCRX8.85x

Revenue (TTM)

KTTA$0

TCRX$7M

Revenue Growth (YoY)

KTTA740.5%

TCRX2.2%

Forward Rev Growth

KTTA0.0%

TCRX42.6%

Gross Margin (TTM)

KTTA100.5%

TCRX0.0%

Operating Margin (TTM)

KTTA0.0%

TCRX0.0%

EBITDA Margin (TTM)

KTTA0.0%

TCRX-1626.5%

Net Margin (TTM)

KTTA0.0%

TCRX-1655.4%

FCF Margin (TTM)

KTTAN/A

TCRX-1665.6%

Net Income (TTM)

KTTA$-21M

TCRX$-118M

FCF (TTM)

KTTA$-18M

TCRX$-118M

EPS (TTM)

KTTA-$0.66

TCRX-$0.91

ROE (TTM)

KTTA-4949.0%

TCRX-10872.0%

ROA (TTM)

KTTA-4681.0%

TCRX-5447.0%

ROIC (TTM)

KTTA-4949.0%

TCRX-8356.0%

Cash

KTTA$46M

TCRX$100M

Debt

KTTA$0

TCRX$33M

Net Cash/Debt

KTTA$46M

TCRX$67M

Current Ratio (TTM)

KTTA26.25x

TCRX3.37x

Quick Ratio (TTM)

KTTA24.91x

TCRX3.23x

Debt/Equity (TTM)

KTTA0.00x

TCRX0.47x

Debt/Assets (TTM)

KTTA0.0%

TCRX0.0%

Interest Coverage (TTM)

KTTAN/A

TCRXN/A

Net Debt/EBITDA (TTM)

KTTA0.00x

TCRX0.00x

Beta

KTTA0.39

TCRX1.19

52W Performance

KTTA-43.0%

TCRX-88.0%

YTD Performance

KTTA-60.7%

TCRX-76.7%

% from 52W High

KTTA-77.3%

TCRX-90.7%

% from 52W Low

KTTA66.4%

TCRX6.1%

Asset Turnover (TTM)

KTTA0.01x

TCRX0.03x

FCF Yield (TTM)

KTTA-113.8%

TCRX-761.5%

Earnings Yield (TTM)

KTTA-136.3%

TCRX-756.8%

Dividend Yield (TTM)

KTTAN/A

TCRXN/A

Rule of 40

KTTA740.5

TCRX-1,663.4

EV/GP/RG

KTTAN/A

TCRXN/A

Ticker research

View KTTA research View TCRX research

Metric	KTTA Pasithea Therapeutics Corp	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$16M	$16M
Enterprise Value	$-30M	$-52M
Price	$0.47	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	26.84x	2.19x
EV/Sales	0.00x	-7.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.32x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	1.69x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.85x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	740.5%	2.2%
Forward Rev Growth	0.0%	42.6%
Profitability
Gross Margin (TTM)	100.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1626.5%
Net Margin (TTM)	0.0%	-1655.4%
FCF Margin (TTM)	N/A	-1665.6%
Net Income (TTM)	$-21M	$-118M
FCF (TTM)	$-18M	$-118M
EPS (TTM)	-$0.66	-$0.91
ROE (TTM)	-4949.0%	-10872.0%
ROA (TTM)	-4681.0%	-5447.0%
ROIC (TTM)	-4949.0%	-8356.0%
Financial Health
Cash	$46M	$100M
Debt	$0	$33M
Net Cash/Debt	$46M	$67M
Current Ratio (TTM)	26.25x	3.37x
Quick Ratio (TTM)	24.91x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	1.19
52W Performance	-43.0%	-88.0%
YTD Performance	-60.7%	-76.7%
% from 52W High	-77.3%	-90.7%
% from 52W Low	66.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.03x
FCF Yield (TTM)	-113.8%	-761.5%
Earnings Yield (TTM)	-136.3%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	740.5	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View KTTA research	View TCRX research